CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis

CONCLUSIONS: At the current drug price, tisagenlecleucel was not found to be a cost-effective option. These results heavily depend on assumptions regarding long-term survival and the price of CAR T. Real-world evidence is needed to reduce uncertainty.HIGHLIGHTS: For patients with diffuse large B-cell lymphoma who failed 2 or more lines of systemic therapy, CAR T was not found to be a cost-effective treatment option at a willingness-to-pay threshold of $100,000.These results heavily depend on the expected long-term survival. The uncertainty in the model may be improved using real-world evidence reported in the future.PMID:38486447 | DOI:10.1177/0272989X241234070

Source: Cancer Control - March 15, 2024 Category: Cancer & Oncology Authors: Lisa Masucci Feng Tian Stephen Tully Zeny Feng Tom McFarlane Kelvin K W Chan William W L Wong Source Type: research